Univercells Technologies has completed a EUR 2 m expansion of the Nivelles, Belgium site. The critical investment was made to deliver a deeper level of support and supply chain security to biomanufacturers.

Univercells Technologies completes Nivelles facility expansion, tripling manufacturing and R&D capacity

Nivelles, Belgium, October 5, 2022 – Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, has completed a EUR 2 m expansion of the Nivelles, Belgium site. The critical investment was made to deliver a deeper level of support and supply chain security to biomanufacturers.

Nivelles site expansion activities began in December 2020 when the company doubled its overall footprint. The initial focus was on expanding warehouse storage as well as the ISO 8 clean room space, greatly increasing capacity for bioreactors and related single use assemblies. Next came remodeling the office and workshop spaces to offer a flexible and modern workplace. The expansion also allows customers to come on site to work in one of the new ‘hands-on’ bioprocess training suites for guidance and support.

Nivelles is a legacy site where we first opened our cleanrooms in March of 2019. We are investing in this site to maximize our manufacturing capabilities and core competencies for customers, while better supporting our employees,” said Mathias Garny, CEO of Univercells Technologies. “Our existing footprint has been increased by 100%, netting a 3x increase in production capacity. We have been able to insource the critical steps of preparation and assembly of our proprietary fixed bed, the key to the superior performance of all our scale-X™ bioreactors.”

Gareth Crothers, Head of Manufacturing & Supply at Univercells Technologies, shares, “We believe that providing a quality work environment for our valued employees is critical to providing the best support to our customers. This investment is a key step to maintaining our highly competitive bioreactor and manifold lead-times of under a month for standard items and maintaining high on time shipment while demand grows. And we will continue to take steps to evolve with the market and ensure security of supply of our capital equipment products, as well as the components needed for our consumable products.”

All expansion activities are complete at the time of release, and new or existing customer inquiries are welcome. Please feel free to contact the team to visit our new demonstration room featuring the flexible and scalable scale-X bioreactor portfolio, as well as the full NevoLine™ Upstream biomanufacturing platform. 

Download the press release

Univercells Technologies - The next evolution of Biomanufacturing

About Univercells Technologies

Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective advanced therapies production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.

Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 following its carve-out from Univercells with the support of the Univercells Group and Gamma Biosciences.

LinkedIn: Univercells Technologies

Subscribe to
our newsletter